1. Home
  2. AAME vs EQ Comparison

AAME vs EQ Comparison

Compare AAME & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlantic American Corporation

AAME

Atlantic American Corporation

HOLD

Current Price

$2.44

Market Cap

50.6M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.21

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAME
EQ
Founded
1968
2017
Country
United States
United States
Employees
156
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AAME
EQ
Price
$2.44
$1.21
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
27.6K
510.3K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
0.80%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
$208,218,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.78
N/A
Revenue Growth
11.99
N/A
52 Week Low
$1.25
$0.27
52 Week High
$3.71
$2.35

Technical Indicators

Market Signals
Indicator
AAME
EQ
Relative Strength Index (RSI) 39.31 59.37
Support Level $2.34 $0.84
Resistance Level $2.62 $1.44
Average True Range (ATR) 0.14 0.12
MACD 0.02 0.06
Stochastic Oscillator 21.64 67.36

Price Performance

Historical Comparison
AAME
EQ

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: